Vertex Pharmaceuticals | VRTX - Ebitda

Aktienkurs
430.29
Täglich Wechseln
-4.81 -1.11%
Monatlich
-5.42%
Jährlich
-12.87%
Q2 Prognose
421.08




Ebitda Veränderung Datum
AbbVie USD 3.52B 828M 2025-09
Acadia Pharmaceuticals USD 35.76M 447K 2025-09
Agios Pharmaceuticals USD -115.49M 10.3M 2025-09
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amgen USD 5.14B 775M 2025-12
Arrowhead Research USD 64.2M 223.53M 2025-09
Biogen USD 573.2M 253.7M 2025-12
BioMarin Pharmaceutical USD -24.17M 18.91M 2025-12
Bristol-Myers Squibb USD 4.24B 967M 2025-09
Gilead Sciences USD 3.02B 1.01B 2025-12
Incyte USD 414.5M 92.42M 2025-12
Insmed USD -314.19M 31.48M 2025-12
Ionis Pharmaceuticals USD -157.12M 307.36M 2025-09
J&J USD 7.19B 2.32B 2025-12
Merck USD 8.39B 1.97B 2025-09
Moderna USD -790M 582M 2025-12
Neurocrine Biosciences USD 218.4M 28.3M 2025-12
Novartis USD 4.77B 1.11B 2025-12
Pfizer USD 6.08B 351M 2025-09
PTC Therapeutics USD -70.99M 91.62M 2025-12
Puma Biotechnology USD 729K 11.36M 2024-06
Regeneron Pharmaceuticals USD 1.92B 261.9M 2025-09
Roche Holding CHF 12.68B 2.36B 2024-06
Sanofi EUR 3.31B 3.65B 2026-03
Sarepta Therapeutics USD -168.03M 294.45M 2025-09
Ultragenyx Pharmaceutical USD -156.79M 65.44M 2025-09
United Therapeutics USD 379.5M 83.4M 2025-12
Vertex Pharmaceuticals USD 1.44B 100.4M 2025-09